Aptus Capital Advisors LLC Raises Stake in GSK plc (NYSE:GSK)

Aptus Capital Advisors LLC raised its position in GSK plc (NYSE:GSK) by 42.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,886 shares of the pharmaceutical company’s stock after acquiring an additional 2,365 shares during the quarter. Aptus Capital Advisors LLC’s holdings in GSK were worth $322,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Eastern Bank purchased a new position in GSK in the third quarter worth approximately $26,000. Concord Wealth Partners lifted its position in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of GSK during the 2nd quarter worth approximately $37,000. Fortitude Family Office LLC purchased a new stake in shares of GSK during the 3rd quarter worth approximately $42,000. Finally, PrairieView Partners LLC purchased a new stake in shares of GSK during the 2nd quarter worth approximately $47,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.9 %

GSK stock opened at $33.35 on Friday. The company has a fifty day moving average price of $39.08 and a 200 day moving average price of $40.69. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a market cap of $69.12 billion, a price-to-earnings ratio of 21.65, a price-to-earnings-growth ratio of 1.35 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.71%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.